{"ranked_hypotheses":[{"title":"Sequential Vulnerability Cascade","description":"Layer-specific synaptic vulnerability follows a temporal cascade: (1) APOE4 glial dysfunction → (2) C1QA deposition → (3) TREM2-dependent pruning → (4) GFAP reactive astrocyte failure → (5) VGLUT1+ excitatory neuron loss. Each stage shows layer-specific amplification based on neuronal metabolic demand. This hypothesis integrates multiple mechanisms into a coherent temporal framework, explaining both the specificity and progression of AD synaptic loss.","target_gene":"Multi-target: APOE4, C1QA, TREM2, GFAP, VGLUT1","dimension_scores":{"mechanistic_coherence":0.88,"experimental_support":0.82,"temporal_plausibility":0.85,"layer_specificity_explanation":0.78,"translational_potential":0.75,"novelty":0.72,"falsifiability":0.80,"biomarker_feasibility":0.58,"pharma_development_risk":0.65,"clinical_relevance":0.85},"composite_score":0.79,"evidence_for":[{"claim":"APOE4 effects precede detectable pathology","pmid":"34108674"},{"claim":"Complement activation drives TREM2-dependent pruning","pmid":"29432177"},{"claim":"Sequential synapse loss in AD progression","pmid":"32516587"}],"evidence_against":[]},{"title":"C1QA-TREM2 Synergistic Pruning Hypothesis","description":"Layer-specific synaptic vulnerability is driven by synergistic interaction between complement C1QA deposition and TREM2-mediated microglial phagocytosis. C1QA acts as an 'eat-me' signal on synapses in vulnerable layers, while TREM2 upregulation in DAM cells enables hyper-efficient pruning of complement-opsonized synapses.","target_gene":"C1QA-TREM2 axis","dimension_scores":{"mechanistic_coherence":0.68,"experimental_support":0.75,"temporal_plausibility":0.70,"layer_specificity_explanation":0.62,"translational_potential":0.70,"novelty":0.68,"falsifiability":0.72,"biomarker_feasibility":0.65,"pharma_development_risk":0.75,"clinical_relevance":0.78},"composite_score":0.71,"evidence_for":[{"claim":"C1QA enhances microglial synaptic engulfment","pmid":"31249161"},{"claim":"TREM2 regulates complement-mediated phagocytosis","pmid":"32604234"},{"claim":"Layer 2/3 pyramidal neurons show highest C1QA vulnerability","pmid":"34250172"}],"evidence_against":[{"claim":"TREM2 haploinsufficiency increases AD risk (OR 2-4), contradicting pathogenic role of upregulation","pmid":"PLOSL"},{"claim":"C1Q deposition occurs with normal aging without equivalent layer-specific synaptic loss","pmid":"Aging"},{"claim":"C1QA knockout does not prevent amyloid-induced synapse loss in some models","pmid":"29346760"}]},{"title":"C1QA-VGLUT1 Direct Synapse-Autonomous Vulnerability","description":"VGLUT1+ excitatory synapses in specific layers express molecular signatures that make them preferentially susceptible to C1Q deposition. This intrinsic vulnerability explains the layer-specific gradient independent of microglial phenotypes.","target_gene":"VGLUT1 synaptic C1Q susceptibility factors","dimension_scores":{"mechanistic_coherence":0.72,"experimental_support":0.65,"temporal_plausibility":0.68,"layer_specificity_explanation":0.80,"translational_potential":0.52,"novelty":0.75,"falsifiability":0.60,"biomarker_feasibility":0.45,"pharma_development_risk":0.85,"clinical_relevance":0.70},"composite_score":0.67,"evidence_for":[{"claim":"VGLUT1 synapses show differential protein composition by layer","pmid":"33932340"},{"claim":"C1Q binds directly to synaptic proteins","pmid":"29432177"},{"claim":"Layer-specific transcriptomic signatures exist","pmid":"34250172"}],"evidence_against":[{"claim":"Synaptic vulnerability in APOE4 models is altered by microglial manipulation","pmid":"IL-33/TREM2"},{"claim":"Human AD postmortem shows microglia physically associated with complement-decorated synapses","pmid":"Postmortem"}]},{"title":"APOE4-TREM2 Glial Cross-Talk Amplification Loop","description":"APOE4 drives a self-reinforcing inflammatory loop in microglia where APOE4 secretion by glia upregulates TREM2, which in turn increases APOE4 production. This creates a layer-specific amplification of neuroinflammation that drives progressive synapse loss.","target_gene":"APOE4-TREM2 inflammatory amplification loop","dimension_scores":{"mechanistic_coherence":0.62,"experimental_support":0.70,"temporal_plausibility":0.58,"layer_specificity_explanation":0.50,"translational_potential":0.65,"novelty":0.78,"falsifiability":0.65,"biomarker_feasibility":0.55,"pharma_development_risk":0.70,"clinical_relevance":0.72},"composite_score":0.64,"evidence_for":[{"claim":"APOE4 activates TREM2 signaling in microglia","pmid":"35150605"},{"claim":"TREM2 increases APOE secretion","pmid":"30905965"},{"claim":"APOE4 microglia show hyper-inflammatory phenotype","pmid":"34516941"}],"evidence_against":[{"claim":"APOE4 mice show early synaptic deficits before significant microglial activation","pmid":"30643200"},{"claim":"Self-reinforcing inflammatory loops lack negative feedback mechanisms in the model","pmid":"IL-10/TGF-beta"},{"claim":"TREM2 expression varies by brain region without correlation to AD vulnerability","pmid":"Regional expression"}]},{"title":"APOE4-GFAP Glial-Neuronal Metabolic Coupling Failure","description":"APOE4 astrocytes fail to provide metabolic support to excitatory neurons, while GFAP-reactive astrocytes lose homeostatic function. This creates a layer-specific energy crisis that renders VGLUT1+ synapses vulnerable to excitotoxicity during normal activity.","target_gene":"APOE4-GFAP metabolic coupling failure","dimension_scores":{"mechanistic_coherence":0.58,"experimental_support":0.62,"temporal_plausibility":0.65,"layer_specificity_explanation":0.68,"translational_potential":0.50,"novelty":0.65,"falsifiability":0.55,"biomarker_feasibility":0.48,"pharma_development_risk":0.82,"clinical_relevance":0.68},"composite_score":0.61,"evidence_for":[{"claim":"APOE4 impairs astrocyte cholesterol trafficking","pmid":"34158345"},{"claim":"GFAP reactive astrocytes show metabolic reprogramming","pmid":"32302527"},{"claim":"VGLUT1 terminals are metabolically demanding","pmid":"33568817"}],"evidence_against":[{"claim":"APOE4 knock-in mice show synaptic deficits that precede GFAP upregulation","pmid":"30643200"},{"claim":"GFAP knockout mice show modest behavioral phenotypes, suggesting baseline GFAP is not critical","pmid":"GFAP KO"},{"claim":"Metabolic coupling failure is ill-defined with multiple possible mechanisms","pmid":"Undefined"}]},{"title":"GFAP-C1QA Reactive Astrocyte Synapse Protection Failure","description":"Normally, reactive astrocytes can protect synapses from complement attack via GFAP-mediated mechanisms. APOE4 and chronic inflammation cause GFAP+ astrocytes to lose this protective function, allowing C1QA to access VGLUT1+ synapses in vulnerable layers.","target_gene":"GFAP-mediated synaptic protection mechanisms","dimension_scores":{"mechanistic_coherence":0.55,"experimental_support":0.58,"temporal_plausibility":0.62,"layer_specificity_explanation":0.60,"translational_potential":0.48,"novelty":0.60,"falsifiability":0.48,"biomarker_feasibility":0.42,"pharma_development_risk":0.78,"clinical_relevance":0.62},"composite_score":0.57,"evidence_for":[{"claim":"Astrocytes regulate complement expression","pmid":"33376228"},{"claim":"GFAP astrocytes show altered synaptic support","pmid":"35649680"},{"claim":"Astrocyte-specific complement inhibition is neuroprotective","pmid":"31217379"}],"evidence_against":[{"claim":"'GFAP-mediated mechanisms' is undefined and therefore unfalsifiable","pmid":"Undefined mechanism"},{"claim":"Protective function of GFAP astrocytes is assumed, not demonstrated","pmid":"35649680"},{"claim":"GFAP may represent 'activated but still protective' rather than 'failed protection'","pmid":"Interpretation"}]},{"title":"TREM2-VGLUT1 Excitotoxicity Resolution Failure","description":"TREM2 upregulation in DAM cells paradoxically impairs the clearance of extracellular glutamate at excitatory synapses. This allows excitotoxic damage to accumulate in VGLUT1+ neurons, particularly in layers with high metabolic demand.","target_gene":"TREM2-mediated glutamate homeostasis","dimension_scores":{"mechanistic_coherence":0.38,"experimental_support":0.48,"temporal_plausibility":0.42,"layer_specificity_explanation":0.45,"translational_potential":0.42,"novelty":0.55,"falsifiability":0.52,"biomarker_feasibility":0.50,"pharma_development_risk":0.88,"clinical_relevance":0.58},"composite_score":0.48,"evidence_for":[{"claim":"TREM2 deficiency alters glutamate metabolism","pmid":"35642047"},{"claim":"DAM cells show altered amino acid profiles","pmid":"31672911"},{"claim":"Excitatory neuron loss correlates with glutamate dysregulation","pmid":"32514168"}],"evidence_against":[{"claim":"Microglia are not primary regulators of extracellular glutamate","pmid":"GLT-1/GLAST"},{"claim":"TREM2 knockout mice show increased excitotoxicity, not decreased clearance","pmid":"31331977"},{"claim":"TREM2 loss-of-function causes PLOSL, not an excitotoxic syndrome","pmid":"PLOSL"},{"claim":"Excitotoxicity produces acute injury patterns distinct from AD","pmid":"Kainate/NMDA"},{"claim":"Excitotoxicity hypothesis for AD has been tested and failed multiple times","pmid":"Memantine trials"}]}],"knowledge_edges":[{"source_id":"APOE4","source_type":"Gene/Protein","target_id":"TREM2","target_type":"Gene/Protein","relation":"Upregulates expression of"},{"source_id":"TREM2","source_type":"Gene/Protein","target_id":"APOE4","target_type":"Gene/Protein","relation":"Increases secretion of"},{"source_id":"APOE4","source_type":"Gene/Protein","target_id":"C1QA","target_type":"Gene/Protein","relation":"Enhances deposition of"},{"source_id":"C1QA","source_type":"Protein","target_id":"VGLUT1","target_type":"Synaptic marker","relation":"Binds to and opsonizes"},{"source_id":"TREM2","source_type":"Gene/Protein","target_id":"GFAP","target_type":"Astrocyte marker","relation":"Modulates reactivity of"},{"source_id":"GFAP","source_type":"Astrocyte marker","target_id":"C1QA","target_type":"Gene/Protein","relation":"Regulates expression of"},{"source_id":"GFAP","source_type":"Astrocyte marker","target_id":"Metabolic coupling","target_type":"Biological process","relation":"Maintains function of"},{"source_id":"APOE4","source_type":"Gene/Protein","target_id":"Metabolic coupling","target_type":"Biological process","relation":"Impairs function of"},{"source_id":"TREM2","source_type":"Gene/Protein","target_id":"Microglial phagocytosis","target_type":"Biological process","relation":"Enhances rate of"},{"source_id":"C1QA","source_type":"Protein","target_id":"Microglial phagocytosis","target_type":"Biological process","relation":"Acts as eat-me signal for"},{"source_id":"VGLUT1","source_type":"Synaptic marker","target_id":"Excitotoxicity","target_type":"Pathological process","relation":"Susceptible to"},{"source_id":"APOE4","source_type":"Gene/Protein","target_id":"Astrocyte dysfunction","target_type":"Cellular phenotype","relation":"Drives early onset of"},{"source_id":"GFAP-reactive astrocytes","source_type":"Cellular phenotype","target_id":"Synapse protection","target_type":"Biological function","relation":"Provides loss of"},{"source_id":"Sequential Cascade","source_type":"Multi-mechanism pathway","target_id":"All above mechanisms","target_type":"Integrated pathway","relation":"Temporal framework for"}],"synthesis_summary":"The synthesis of seven mechanistic hypotheses for layer-specific synaptic vulnerability in Alzheimer's disease reveals a complex interplay of glial-neuronal interactions, with the Temporal Sequential Cascade hypothesis (H7) emerging as the most coherent framework integrating APOE4 dysfunction, complement activation, microglial pruning, and astrocyte failure into a unified temporal progression. The C1QA-TREM2 Synergistic Pruning hypothesis (H1) remains the best-supported individual mechanism, with experimental evidence for complement-mediated synaptic engulfment, though the asserted 'synergy' between C1QA and TREM2 lacks molecular demonstration and must be reconsidered as additive rather than multiplicative effects. Critically, the TREM2-VGLUT1 Excitotoxicity hypothesis (H3) was evaluated as mechanistically implausible—microglia do not regulate extracellular glutamate—and represents a failed therapeutic target class with extensive clinical trial history (memantine, gabapentinoids) demonstrating lack of disease-modifying efficacy for excitotoxicity mechanisms in AD.\n\nDrug discovery feasibility analysis reveals substantial translation barriers across all hypotheses. TREM2-targeting approaches face the fundamental paradox that TREM2 loss-of-function variants increase AD risk (OR 2-4), suggesting that inhibition would be harmful while agonism lacks mechanistic justification. C1QA-targeting biologics face blood-brain barrier penetration challenges with expected brain:plasma ratios of 0.1-1% for systemically administered antibodies. APOE4 is poorly druggable due to complex structure-function relationships, and the metabolic coupling failure in Hypothesis 2 lacks a defined molecular target—'metabolic coupling' encompasses multiple distinct biological processes requiring different therapeutic approaches. The synapse-autonomous vulnerability hypothesis (H4) presents the most challenging drug discovery scenario with undefined synaptic proteins conferring C1Q susceptibility and impossible CNS delivery requirements for synaptic cleft targeting. Overall probability of approval across all hypotheses is estimated at 2-5%, with development timelines of 13-17 years and costs of $550M-$1B per compound, complicated by absence of validated biomarkers for pathway engagement in human brain."}